Autolomous and Cellular Origins announced end-to-end integration of their cell therapy manufacturing platforms, aiming to deliver a fully automated and digitized workflow. The combined approach is framed around standardization, traceability, and improved control across cell therapy production—from manufacturing steps to real-time data exchange. The partners say early integrations have been completed in digital and automation testbeds connected to the Cell and Gene Therapy Catapult program, signaling a push toward production environments that reduce manual variability and speed scaling. This is the kind of operational milestone that can materially affect cost, batch consistency, and regulatory readiness for sponsors seeking to broaden access to cell therapies.